81.7 Reasons Why GlaxoSmithKline plc Is A Stunning Stock Pick

Royston Wild looks at why GlaxoSmithKline plc (LON: GSK) is a stellar selection for dividend hunters.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In this article I am looking at why GlaxoSmithKline’s (LSE: GSK) (NYSE: GSK.US) resurgent development pipeline bodes well for income growth.

A delightful dividend outlook

Even though GlaxoSmithKline has experienced volatile earnings performance in recent years, the company’s formidable cash pile has enabled it to keep its progressive dividend policy on track. The drugs giant has raised payouts at a compound annual growth rate of 6.3% since 2009, and City brokers expect the company to lift the full-year dividend again in 2014, to a whopping 81.7p per share.

If realised, such a payout would represent an inflation-beating 4.7% improvement from 2013’s dividend. And this projection creates a mammoth 5.1% yield, far in excess of a prospective average of 2.5% for the complete pharmaceuticals and biotechnology sector. And the yield edges to 5.2% next year, when GlaxoSmithKline is anticipated to hike the total payout 3.6% to 84.6p.

On top of this, GlaxoSmithKline plans to execute between £1bn and £2bn worth of share repurchases in the current year, making it an attractive pick for income investors.

GlaxoSmithKline continues to suffer from patent losses across its key drugs, and announced in April that, at constant exchange rates, total sales declined 2% to £5.6bn during January-March. The company’s Lovaza triglycerides-battling brand is the latest product to lose exclusivity, but GlaxoSmithKline is chucking vast sums of capital to boost its drugs pipeline and offset eroding barriers to entry.

The drugs testing process is of course a bumpy process, and GlaxoSmithKline received a setback this month when Phase III evaluations of its potentially-blockbusting darapladib product — used to treat those suffering from acute coronary conditions — failed at the second time of asking.

But broadly speaking the company has been hugely successful in getting its products to market. In May the company received authorisation from the European Commission for its Anoro medication, used to treat the symptoms of chronic obstructive pulmonary disease (COPD) and paving the way for roll-out by the close of September. And in North America its COPD-soothing Incruse Ellipta treatment was also given the green light for launch by the US Food and Drug Administration.

GlaxoSmithKline currently has around 40 more products in late stage development, a promising omen for future revenues growth. With its bubbly drug pipeline ready to deliver the next generation of revenues-driving products, and with it the prospect of strapping earnings growth, I believe that the pharma play is an excellent choice for those seeking lucrative income flows.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston does not own shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »